Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cephalothin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in Gram-positive bacteria.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
FDA-approved: Treatment of respiratory tract infections, skin and soft tissue infections, bone and joint infections, septicemia, and urinary tract infections caused by susceptible organisms,Off-label: Prophylaxis in surgery, treatment of endocarditis
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
1-2 g IV every 4-6 hours; maximum 12 g/day.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
0.5-1 hour; prolonged in renal impairment (up to 8-12 hours in anuria)
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Cephalothin is metabolized in the liver by deacetylation to desacetylcephalothin, which has less antimicrobial activity. The enzyme responsible is not specifically identified but involves hepatic esterases.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal excretion (60-70% unchanged); biliary excretion (20-30%); fecal elimination (<1%)
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
65-80% bound to serum albumin
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
0.2-0.3 L/kg; primarily extracellular fluid
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100%; intramuscular: approximately 50-60%
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Cr Cl 50-80 m L/min: no adjustment; Cr Cl 25-50 m L/min: 1-2 g every 6-8 hours; Cr Cl 10-25 m L/min: 1-2 g every 8-12 hours; Cr Cl <10 m L/min: 1-2 g every 12-24 hours.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific dose adjustment recommended; use caution in severe hepatic impairment.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
100-150 mg/kg/day IV divided every 6 hours; maximum 12 g/day.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
No specific adjustment; consider renal function and reduce dose if Cr Cl <50 m L/min.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Hypersensitivity reactions: Cross-allergenicity with other beta-lactams, including penicillins; anaphylaxis may occur,Pseudomembranous colitis: Clostridium difficile-associated diarrhea can develop,Renal impairment: Dosage adjustment required due to renal excretion; monitor renal function,Bleeding risk: May potentiate anticoagulants; monitor prothrombin time,False-positive urine glucose test: With Clinitest or Benedict's solution, but not with glucose oxidase methods
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to cephalothin, any cephalosporin, or other beta-lactam antibiotics,Absolute: Known anaphylactic reaction to penicillins due to cross-sensitivity
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No significant food interactions. Absorption is not affected by food. Avoid alcohol during treatment and for 72 hours after completion to prevent disulfiram-like reaction (reported with some cephalosporins, though rare with cephalothin).
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Cephalothin is a first-generation cephalosporin classified as FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal risk, and there are no adequate and well-controlled studies in pregnant women. However, systemic absorption is expected to be low with intraperitoneal administration. First trimester: No evidence of teratogenicity, but data limited. Second/third trimesters: Generally considered safe; cross the placenta with therapeutic concentrations achieved in fetal serum and amniotic fluid. No known association with congenital malformations.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Cephalothin is excreted into human breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.02–0.05. For a maternal dose of 1 g intravenously, the estimated infant dose is <1% of the therapeutic dose. Considered compatible with breastfeeding but monitor infant for potential gastrointestinal effects (e.g., diarrhea, candidiasis) or allergic reactions.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy-induced physiological changes (increased plasma volume, enhanced renal clearance) may reduce serum cephalothin concentrations. However, no formal dosing adjustments are recommended; standard adult dosing is used. For severe infections, monitor clinical response and consider higher doses if needed.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Cephalothin is a first-generation cephalosporin with activity against gram-positive cocci (excluding MRSA and enterococci) and some gram-negative rods. It is often used perioperatively for surgical prophylaxis. Note that cephalothin is not active against Pseudomonas aeruginosa, Bacteroides fragilis, or Enterobacter species. Cross-allergenicity with penicillins occurs in approximately 5-10% of patients. Administer before meals if GI upset occurs. Monitor renal function in elderly or those with preexisting renal impairment, as cephalothin may accumulate and cause nephrotoxicity. Pain at injection site and phlebitis are common with IV administration.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Take this medication exactly as prescribed, even if you feel well.,Complete the full course of therapy to prevent resistance.,Report any signs of allergic reaction such as rash, itching, swelling, or difficulty breathing immediately.,Inform your healthcare provider if you have a history of penicillin allergy.,If you experience severe diarrhea, especially with blood or mucus, contact your doctor (possible C. difficile colitis).,Use effective contraception during treatment, as cephalothin may reduce efficacy of oral contraceptives.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER is a Electrolyte that works by Cephalothin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in Gram-positive bacteria.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER is: 1-2 g IV every 4-6 hours; maximum 12 g/day.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER is classified as Category A/B. Cephalothin is a first-generation cephalosporin classified as FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal risk, and there are no adequate and . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.